These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26163345)

  • 1. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
    Omae K; Kondo T; Kennoki T; Takagi T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
    Int J Clin Oncol; 2016 Feb; 21(1):126-32. PubMed ID: 26163345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
    Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
    Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
    Kim SH; Kim S; Nam BH; Lee SE; Kim CS; Seo IY; Kim TN; Hong SH; Kwon TG; Seo SI; Joo KJ; Song K; Kwak C; Chung J
    PLoS One; 2015; 10(8):e0135165. PubMed ID: 26308612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
    Akaza H; Oya M; Iijima M; Hyodo I; Gemma A; Itoh H; Adachi M; Okayama Y; Sunaya T; Inuyama L
    Jpn J Clin Oncol; 2015 Oct; 45(10):953-62. PubMed ID: 26206897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
    Leonetti A; Bersanelli M; Castagneto B; Masini C; Di Meglio G; Pellegrino B; Buti S
    Clin Genitourin Cancer; 2016 Aug; 14(4):277-83. PubMed ID: 26899142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
    Zhang Y; Li Y; Cai Y; Wang K; Li H
    Cell Oncol (Dordr); 2016 Feb; 39(1):15-21. PubMed ID: 26597814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
    Jäger D; Ma JH; Mardiak J; Ye DW; Korbenfeld E; Zemanova M; Ahn H; Guo J; Leonhartsberger N; Stauch K; Böckenhoff A; Yu J; Escudier B
    Clin Genitourin Cancer; 2015 Apr; 13(2):156-64.e1. PubMed ID: 25444666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
    Matsubara N; Mukai H; Naito Y; Itoh K; Komai Y; Sakai Y
    Urology; 2013 Jul; 82(1):118-23. PubMed ID: 23806397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
    Naito S; Sakai H; Hashine K; Tomita Y; Shinohara N; Fujisawa M; Eto M; Ozono S; Akaza H
    Ann Oncol; 2015 Sep; 26(9):1871-1876. PubMed ID: 26117830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.
    Shetty AV; Matrana MR; Atkinson BJ; Flaherty AL; Jonasch E; Tannir NM
    Clin Genitourin Cancer; 2014 Oct; 12(5):348-53. PubMed ID: 24565697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
    Miyake H; Miyazaki A; Imai S; Harada K; Fujisawa M
    Target Oncol; 2016 Apr; 11(2):175-82. PubMed ID: 26341668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
    Procopio G; Derosa L; Gernone A; Morelli F; Sava T; Zustovich F; De Giorgi U; Ferrari V; Sabbatini R; Gasparro D; Felici A; Burattini L; Calvani N; Lo Re G; Banna G; Pia Brizzi M; Rizzo M; Ciuffreda L; Iacovelli R; Ferraù F; Taibi E; Bracarda S; Porta C; Galligioni E; Contu A
    Future Oncol; 2014 Aug; 10(10):1741-50. PubMed ID: 24641206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
    Masini C; Sabbatini R; Porta C; Procopio G; Di Lorenzo G; Onofri A; Buti S; Iacovelli R; Invernizzi R; Moscetti L; Aste MG; Pagano M; Grosso F; Lucia Manenti A; Ortega C; Cosmai L; Del Giovane C; Conte PF
    BJU Int; 2012 Sep; 110(5):692-8. PubMed ID: 22364110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.